FEATURES OF COURSE AND RESULTS OF TREATMENT OF BODY SKIN MELANOMA


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents an analysis of the features of the course and survival of 304 patients with body skin melanoma (BSM), who underwent surgical treatment in the Crimean Republican Clinical Oncological Dispensary in the period from 1982 to 2004, depending on the location of tumor and different surgical tactics. The most «vulnerable» age group for the development of DSM included patients 41 to 60 years - 42.1±2.8% (53.9% women, 46.1% men). Assessing the long-term results of surgical treatment of BSM in the overall cohort of patients (n=304), it should be noted that 11.3% of the patients died during the first year, 3-year survival rate was 64.4±28%, 5-year survival rate - 53.8±2.9%, 10-year survival rate - 41.0±2.9%. It has been shown that various localization of BSM does not significantly affect the features of the course, the nature of metastasis and the depth of tumor invasion. Simultaneous lymphadenectomy in the absence of morphological confirmation of melanoma metastases in regional lymph nodes is not justified (diagnosis is not confirmed in 43.4±5.0% of patients). Metastases in regional lymph nodes should be considered as a factor of unfavorable course, which significantly reduces life expectancy and survival of patients. Expectant management of patients after the removal of the primary tumor which consists of a delayed lymph node dissection only in the case of appearance of clinical signs of lymph node metastases does not worsen the survival.

Texto integral

Acesso é fechado

Sobre autores

G. Telkieva

FSAEI HE “Crimean Federal University n.a. V.I. Vernadsky"

Email: dr.hilfiger@gmail.com
Department of Oncology of the Medical Academy n.a. S.I. Georgievsky Simferopol

Bibliografia

  1. Jemal A., Bray F., Center M. M., FerlayJ., Ward E., Forman D. Global Cancer Statistics. - CA Cancer. J. Clin. 2011;61:69-90.
  2. Меланоцитарные невусы и меланома кожи / Под ред. В.А. Молочкова, Л.В. Демидова. М., 2012. 112 с.
  3. Каприн А.Д, Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М., 2015. 250 с.
  4. Ball N. F., John J.J., Morelli J.G., Norris D.A., Golitz L.E., Hoeffler J.P. Ras mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol. 1994;102:285.
  5. Территориальный популяционный канцеррегистр ГБУЗРК «КРОКД им. В.М. Ефетова», 2014.
  6. Bachaud J.-M., Shuhinshi R., Boussin G., Chevreau C., David J.M., Viraben R., Bonafe J.L., Daly N.J. Stage I cutaneous Malignant melanoma: risk factors of locoregional recurrence after wide local excision and clinical perspectives. Eur. J. Surg. Oncol. 1992; 18:442-48.
  7. Keefe M., Mackie R.M. The relationship between risk of death from clinical stage I cutaneous melanoma and thickness of primary tumor 10 evidence for steps in risk. Br. J. Cancer. 1991;64:598.
  8. Daryanani D., Plukkerj Th.,deJong M.A.,Haaxma- Reiche H., Nap R., Kuiper H., Hoekstra H.J. Increased incidence of brain metastases in cutaneous head and neck melanoma. Melanoma Res. 2005;15:119-29.
  9. Марочко А.Ю. Меланома кожи 1 стадии: факторы и отдаленные результаты хирургического лечения. Дальневост. мед. журн. 2009;1:49-51.
  10. Тарков С.А., Михнин А.Е., Шелехова К.В., Фролова P.C., Нефедов А.О. Особенности меланом кожи головы и шеи и факторы, влияющие на выживаемость больных. Вопросы онкологии. 2013;59(1):114-17.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies